Saturday, February 02, 2008 9:00:06 AM
Not much new from the earlier conference. Some brief points (all 191 related):
1-Dr. Porter made a passing remark that could be taken that 191 BID dosing went well (something to the effect of better dosing then other PI's)
2-4th cohort may be done based on safety/tolerability.
3-Q2 still plan for starting combination trial
4-On track to release data from first 3 cohorts around end of quarter
5-Said Roche can and will design studies with all combinations of anti-virals in their portfolio. Hinted at doing this particular in the true non-responders.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM